Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Aaron Mitchell Profile picture
Aaron Mitchell
@TheWonkologist
Medical oncologist and health services researcher @MSKCancerCenter. Health care costs, oncology reimbursement reform, PokemonGo. No COI. Ravenclaw.
Oct 25, 2023 • 25 tweets • 7 min read
Our new study is out today in The BMJ @bmj_latest!

Can receiving drug industry money lead oncologists to provide WORSE care?
The answer we found appears to be “yes”…

🧵 to follow
1/
 bmj.com/content/383/bm…
Image First, some context. We previously reviewed all studies asking, "can industry money lead doctors to provide DIFFERENT care?" The answer to that question, as we reported in
@AnnalsofIM , is a resounding "YES"

2/
Sep 29, 2023 • 17 tweets • 4 min read
Lot's of good discussion on this recent, important study in @JCO_ASCO led by my colleague @ErinGillespieMD. Honored to have had the chance to make a (small!) contribution.

My 2 cents on how we should interpret the findings...
1/ This study met its primary endpoint:
RT to asymptomatic, high-risk bone lesions appears to prevent SREs. This is a promising and exciting finding.
SREs can result in devastating loss in quality of life for patients, and any tools to prevent them are welcome.
2/
Jul 22, 2022 • 21 tweets • 8 min read
"Should pharma paying physicians be illegal?"

This is the wrong question. We should be asking:
"Given that pharma paying physicians is already illegal, why does it continue?"

As @AmeetSarpatwari @peterbachmd and I argue today in @JHPPL:
read.dukeupress.edu/jhppl/article/…

🧵 1/ Our argument focuses on the anti-kickback statute (AKS).

CMS OIG has outlined what qualifies as a potentially-prosecutable kickback under AKS. And it prosecutes egregious examples of pharma bribes. But its definition of "kickback" applies much more broadly

2/
Dec 4, 2020 • 8 tweets • 3 min read
Intravesical nadofaragene for BCG-refractory NMIBC.
A single-arm trial.
I have a couple of questions.
thelancet.com/journals/lanon…
1/ Historical context for this trial is important. In 2014, @US_FDA convened a meeting of clinical experts to advise on trial design for non-muscle-invasive bladder cancer, an area of unmet clinical need.
pubmed.ncbi.nlm.nih.gov/24332121/
2/
Nov 24, 2020 • 21 tweets • 9 min read
"Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing?"
Our latest on physician-industry COI is out today in @AnnalsofIM!

Not to bury the lede, the answer is "yes."
Thread to follow.
acpjournals.org/doi/10.7326/M2…
1/ First things first, huge thanks to everyone on the research team: Niti Trivedi, Susan Chimonas, Sara Tabatabai, Johanna Goldberg @mskcc_library, Renee Gennarelli, @ldiaz1, @DKorenstein. This was an enormous amount of work that we are all proud of.
2/
Aug 6, 2020 • 9 tweets • 4 min read
Our new paper in @JNCCN yesterday examines trends in the number of women serving on @NCCN Guidelines panels in recent years:
jnccn.org/view/journals/…
@peterbachmd @DeyPranam
1/ We manually extracted the membership from the Guidelines committees for the 21 most prevalent cancers in the US.
First, the good news.
The proportion of women increased, up to about 32% from 22% over just the last 6 years.
2/
May 24, 2020 • 8 tweets • 3 min read
“How is this legal?”
I reliably get this reaction when I explain aspects of oncology to friends&family, both medical and non.

In my mind, the fact that current practices run afoul of commonly-held ethical sensibilities is a clear mandate for change.
1/ What do I mean, specifically?
I’m referring to the “open secrets” of oncology, which we take for granted but which many people (in my experience) find appalling:
2/
Jan 5, 2020 • 8 tweets • 5 min read
Re-upping our @JAMAOnc systematic review on its 1-year publication anniversary. We searched for studies that asked the question, “do oncologists make treatment decisions based on how lucrative different treatments are?”
1/
 jamanetwork.com/journals/jamao… We found that the majority of studies (15 of 18) asking this question concluded that yes, personal and/or practice revenue is a consideration in choosing anti cancer treatments.
2/
Jul 31, 2019 • 13 tweets • 4 min read
I don't wish this idea would go away. I wish this idea would increase.

Unnecessary stress tests:
jamanetwork.com/journals/jama/…
1/ Chemotherapy to patients at the end of life:
ncbi.nlm.nih.gov/pubmed/22942834
2/
Nov 13, 2018 • 8 tweets • 3 min read
I'm sensing a new wave of reports on cancer "overtaking" or "surpassing" heart disease as leading cause of death in the US.
Here's your friendly reminder that this is a story about which cause of death is decreasing more quickly. Source for graph is CDC:
cdc.gov/mmwr/preview/m…
I've been looking for a version with more recent data than 2011...if anyone out there has one, please send!
Nov 8, 2018 • 10 tweets • 5 min read
1/ Time for a quick lit review on whether docs getting money from drug companies influences their prescribing behavior!
#healthpolicy #COI 2/ Among similar TNF-alpha blockers, physicians who got paid by one company were more likely to use that company's drug over others.
ncbi.nlm.nih.gov/pubmed/30324292 @AdeAdamson